121 related articles for article (PubMed ID: 9698485)
1. Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Prontera C; Facchini V; Bianchi R; Genazzani AR
Gynecol Oncol; 1998 Jul; 70(1):111-4. PubMed ID: 9698485
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Gagetti O; Prontera C; Bianchi R; Facchini V
Gynecol Oncol; 1995 Aug; 58(2):184-8. PubMed ID: 7542621
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
4. [Macrophage-colony stimulating factor and ovarian cancer].
Menditto A; Piscittelli V; Cassese F; Balbi GC; Balbi C; Cardone A
Minerva Ginecol; 1999; 51(7-8):261-4. PubMed ID: 10536419
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
[TBL] [Abstract][Full Text] [Related]
6. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
[TBL] [Abstract][Full Text] [Related]
7. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
ławicki S; Czygier M; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Pol Merkur Lekarski; 2006 Nov; 21(125):465-8. PubMed ID: 17345841
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
9. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
10. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary.
Suzuki M; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 1998 Jan; 68(1):35-7. PubMed ID: 9454657
[TBL] [Abstract][Full Text] [Related]
11. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum E-cadherin assay in patients with ovarian carcinoma.
Gadducci A; Ferdeghini M; Cosio S; Annicchiarico C; Ciampi B; Bianchi R; Genazzani AR
Anticancer Res; 1999; 19(1B):769-72. PubMed ID: 10216491
[TBL] [Abstract][Full Text] [Related]
13. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
14. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K
Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
16. Elevated endogenous serum macrophage colony-stimulating factor in the early stage of fungemia following bone marrow transplantation.
Petros WP; Rabinowitz J; Stuart AR; Gupton C; Alderman EM; Peters WP
Exp Hematol; 1994 Jul; 22(7):582-6. PubMed ID: 8013574
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of macrophage colony-stimulating factor in human fracture healing.
Sarahrudi K; Mousavi M; Thomas A; Eipeldauer S; Vécsei V; Pietschmann P; Aharinejad S
J Orthop Res; 2010 May; 28(5):671-6. PubMed ID: 19950360
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
19. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
[TBL] [Abstract][Full Text] [Related]
20. Serum endostatin levels in patients with epithelial ovarian cancer.
Hata K; Dhar DK; Kanasaki H; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Nagasue N; Miyazaki K
Anticancer Res; 2003; 23(2C):1907-12. PubMed ID: 12820477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
